“The CSL stock technical momentum has finally improved,” Raymond said.

“We continue to view CSL as a key portfolio holding and sector pick, offering

double-digit recovery in earnings growth, as plasma collections increase, new products get approved and influenza vaccine uptake increases around ongoing concerns about respiratory viruses, with shares trading at 25x, a substantial discount (20%) to its long-term average,” Raymond said.

GRAPH FOR CSL

Important: This content has been prepared without taking account of the objectives, financial situation or needs of any particular individual. It does not constitute formal advice. Consider the appropriateness of the information in regard to your circumstances.